Th22 Cell Is a Gradually Proved Potential Biomarker for Acute Coronary Syndrome

Abstract EN

Th22 cell, a novel human CD4+ T helper subset, has already been reported to play a vital role in the process of chronic inflammatory diseases such as rheumatoid arthritis (RA) and atherosclerosis (AS) [1, 2].

Interestingly, Th22 cells were also involved in acute coronary syndrome (ACS).

Lin et al.

found that circulating frequencies of Th22 cells and their effector cytokine IL-22 levels were manifestly increased in patients with acute myocardial infarction (AMI), unstable angina pectoris (UAP), and stable angina pectoris (SAP) compared with patients without coronary artery disease (CAD), indicating that plasma of Th22 cells played key roles at the early stage of ACS [3].

It was well accepted that CD4+ T helper cells were intimately associated with the process of ACS [4]; of note, Lin et al.

firstly revealed the relationship between Th22 cells and ACS, providing a new and valuable evidence about the role of Th22 cells in ACS [1].